Skip to main content
SpringerLink
Log in

Sublingual Zolpidem (Edluar™; Sublinox™)

  • Adis Drug Profile
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

Zolpidem is a non-benzodiazepine hypnotic used in the short-term treatment of insomnia. A sublingual orally disintegrating tablet formulation of zolpidem (Edluar™; Sublinox™) has been developed to provide a more rapid onset of action than oral immediate-release zolpidem. Sublingual zolpidem has demonstrated bioequivalence to oral zolpidem. In a randomized, double-blind, double-dummy, crossover, multi-centre study in adult patients with primary insomnia (n = 70), a single 10-mg dose of sublingual zolpidem significantly reduced latency to persistent sleep (primary endpoint) compared with a single 10-mg dose of oral immediate-release zolpidem. Sleep-onset latency and latency to stage 1 sleep were also significantly shorter with sublingual zolpidem than with oral zolpidem. Moreover, compared with the oral formulation, sublingual zolpidem was noninferior in terms of total sleep time and did not significantly differ in terms of duration of wake after sleep onset. Sublingual zolpidem was generally well tolerated in this trial, with most adverse events being of mild or moderate severity. The overall tolerability profile of sublingual zolpidem was similar to that of oral zolpidem.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.

    Google Scholar 

  2. Morin CM, LeBlanc M, Bélanger L, et al. Prevalence of insomnia and its treatment in Canada. Can J Psychiatry. 2011;56(9):540–8.

    PubMed  Google Scholar 

  3. Wilson SJ, Nutt DJ, Alford C, et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol. 2010;24(11):1577–601.

    Article  PubMed  CAS  Google Scholar 

  4. Taylor DJ, Mallory LJ, Lichstein KL, et al. Comorbidity of chronic insomnia with medical problems. Sleep. 2007;30(2):213–8.

    PubMed  Google Scholar 

  5. Skaer TL, Sclar DA. Economic implications of sleep disorders. Pharmacoeconomics. 2010;28(11):1015–23.

    Article  PubMed  Google Scholar 

  6. Roth T, Coulouvrat C, Hajak G, et al. Prevalence and perceived health associated with insomnia based on DSM-IV-TR; International Statistical Classification of Diseases and Related Health Problems, tenth revision; and Research Diagnostic Criteria/International Classification of Sleep Disorders, Second Edition Criteria: results from the America Insomnia Survey. Biol Psychiatry. 2011;69(6):592–600.

    Article  PubMed  Google Scholar 

  7. Schutte-Rodin S, Broch L, Buysse D, et al. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med. 2008;4(5):487–504.

    PubMed  Google Scholar 

  8. Morgenthaler T, Kramer M, Alessi C, et al. Practice parameters for the psychological and behavioral treatment of insomnia: an update: an American Academy of Sleep Medicine report. Sleep. 2006;29(11):1415–9.

    PubMed  Google Scholar 

  9. Passarella S, Duong MT. Diagnosis and treatment of insomnia. Am J Health Syst Pharm. 2008;65(10):927–34.

    Article  PubMed  CAS  Google Scholar 

  10. Owen RT. Novel zolpidem formulations. Drugs Today (Barc). 2009;45(5):395–400.

    Article  CAS  Google Scholar 

  11. Sanofi-Aventis US LLC. Ambien® (zolpidem tartrate) tablets: US prescribing information (online). 2012. http://products.sanofi.us/ambien/ambien.pdf. Accessed 4 Jul 2012.

  12. Sanofi-Aventis. Stilnoct (zolpidem tartrate) 5 mg oral tablets: summary of product characteristics (online). 2012. http://www.medicines.org.uk/EMC/medicine/25408/SPC/Stilnoct+5mg+Tablets/. Accessed 4 Jul 2012.

  13. Sanofi-Aventis. Stilnoct (zolpidem tartrate) 10 mg oral tablets: summary of product characteristics (online). 2012. http://www.medicines.org.uk/EMC/medicine/25411/SPC/Stilnoct+10mg+Tablets/. Accessed 4 Jul 2012.

  14. Sanofi-Aventis US LLC. Ambien CR® (zolpidem tartrate extended-release) tablets: US prescribing information (online). (2012). http://products.sanofi.us/ambien_cr/ambienCR.pdf. Accessed 4 Jul 2012.

  15. NovaDel Pharma Inc. Zolpimist (zolpidem tartrate) oral spray: US prescribing information (online). (2012). http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022196lbl.pdf. Accessed 4 Jul 2012.

  16. Moen MD, Plosker GL. Zolpidem extended-release. CNS Drugs. 2006;20(5):419–26.

    Article  PubMed  CAS  Google Scholar 

  17. Meda AB. Sublinox™ (zolpidem tartrate) 5 mg and 10 mg sublingual orally disintegrating tablets (ODT): Canadian product monograph. Montreal: Valeant Pharma Canada Inc.; 2012.

    Google Scholar 

  18. Meda Pharmaceuticals Inc. Edluar™ (zolpidem tartrate sublingual tablets): US prescribing information (online). (2012). http://www.edluar.com/EDLUAR-PI.pdf. Accessed 4 Jul 2012.

  19. Meda AB. Edluar (zolpidem tartrate) 5, 10 mg sublingual tablets: summary of product characteristics. Solna: Meda AB; 2012.

    Google Scholar 

  20. Transcept Pharmaceuticals, Inc. Intermezzo® (zolpidem tartrate) sublingual tablets: US prescribing information (online). (2012). http://www.transcept.com/images/stories/docs/intermezzo_pi_23nov_2011.pdf. Accessed 4 Jul 2012.

  21. Swainston Harrison T, Keating GM. Zolpidem: a review of its use in the management of insomnia. CNS Drugs. 2005;19(1):65–89.

    Google Scholar 

  22. Scharf MB, Roth T, Vogel GW, et al. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry. 1994;55(5):192–9.

    PubMed  CAS  Google Scholar 

  23. Lahmeyer H, Wilcox CS, Kann J, et al. Subjective efficacy of zolpidem in outpatients with chronic insomnia: a double-blind comparison with placebo. Clin Drug Invest. 1997;13(3):134–44.

    Article  CAS  Google Scholar 

  24. Roth T, Roehrs T, Vogel G. Zolpidem in the treatment of transient insomnia: a double-blind, randomized comparison with placebo. Sleep. 1995;18(4):246–51.

    PubMed  CAS  Google Scholar 

  25. Scharf MB, Mayleben DW, Kaffeman M, et al. Dose response effects of zolpidem in normal geriatric subjects. J Clin Psychiatry. 1991;52(2):77–83.

    PubMed  CAS  Google Scholar 

  26. Staner L, Eriksson M, Cornette F, et al. Sublingual zolpidem is more effective than oral zolpidem in initiating early onset of sleep in the post-nap model of transient insomnia: a polysomnographic study. Sleep Med. 2009;10(6):616–20.

    Article  PubMed  CAS  Google Scholar 

  27. Kasim S. US FDA medical review of zolpidem tartrate sublingual tablet (online). (2012). http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/021997s000_MedR.pdf. Accessed 4 Jul 2012.

  28. Piergies AA, Sweet J, Johnson M, et al. The effect of co-administration of zolpidem with fluoxetine: pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther. 1996;34(4):178–83.

    PubMed  CAS  Google Scholar 

  29. Vlase L, Popa A, Neag M, et al. Effect of fluvoxamine on the pharmacokinetics of zolpidem: a two-treatment period study in healthy volunteers. Clin Exp Pharmacol Physiol. 2012;39(1):9–12.

    Article  PubMed  CAS  Google Scholar 

  30. Cysneiros RM, Farkas D, Harmatz JS, et al. Pharmacokinetic and pharmacodynamic interactions between zolpidem and caffeine. Clin Pharmacol Ther. 2007;82(1):54–62.

    Article  PubMed  CAS  Google Scholar 

  31. Vlase L, Popa A, Neag M, et al. Pharmacokinetic interaction between zolpidem and carbamazepine in healthy volunteers. J Clin Pharmacol. 2011;51(8):1233–6.

    Article  PubMed  CAS  Google Scholar 

  32. Otmani S, Demazières A, Staner C, et al. Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers. Hum Psychopharmacol. 2008;23(8):693–705.

    Article  PubMed  CAS  Google Scholar 

  33. Hojo Y, Echizenya M, Ohkubo T, et al. Drug interaction between St John’s wort and zolpidem in healthy subjects. J Clin Pharm Ther. 2011;36(6):711–5.

    Article  PubMed  CAS  Google Scholar 

  34. Vlase L, Popa A, Neag M, et al. Pharmacokinetic interaction between zolpidem and ciprofloxacin in healthy volunteers. Eur J Drug Metab Pharmacokinet. 2011;35(3–4):83–7.

    Article  PubMed  CAS  Google Scholar 

  35. Farkas D, Volak LP, Harmatz JS, et al. Short-term clarithromycin administration impairs clearance and enhances pharmacodynamic effects of trazodone but not of zolpidem. Clin Pharmacol Ther. 2009;85(6):644–50.

    Article  PubMed  CAS  Google Scholar 

  36. Staner C, Joly F, Jacquot N, et al. Sublingual zolpidem in early onset of sleep compared to oral zolpidem: polysomnographic study in patients with primary insomnia. Curr Med Res Opin. 2010;26(6):1423–31.

    Article  PubMed  CAS  Google Scholar 

  37. Victorri-Vigneau C, Dailly E, Veyrac G, et al. Evidence of zolpidem abuse and dependence: results of the French Centre for Evaluation and Information on Pharmacodependence (CEIP) network survey. Br J Clin Pharmacol. 2007;64(2):198–209.

    Article  PubMed  Google Scholar 

  38. Kripke DF, Langer RD, Kline LE. Hypnotics’ association with mortality or cancer: a matched cohort study. BMJ Open. 2012;2(1):e000850.

    Article  PubMed  Google Scholar 

  39. Meda AB. Edluar approved in Europe (media release). 2012 Jun 15 (online). (2012). http://mb.cision.com/Main/357/9273591/22823.pdf. Accessed 14 Sep 2012.

  40. DocGuide.com. Sublingual zolpidem approved in Canada for insomnia (online). (2011). http://www.docguide.com/sublingual-zolpidem-approved-canada-insomnia. Accessed 20 Dec 2011.

Download references

Acknowledgments

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the authors on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, 0754, Auckland, New Zealand

    Lily P. H. Yang & Emma D. Deeks

Authors
  1. Lily P. H. Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Emma D. Deeks
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lily P. H. Yang.

Additional information

The manuscript was reviewed by: R. Göder, Department of Psychiatry and Psychotherapy, Christian Albrechts University, Kiel, Germany; D.N. Neubauer, Department of Psychiatry and Behavioral Sciences, Johns Hopkins Medical Institutions, Baltimore, MD, USA; E.F. Pace-Schott, Department of Psychiatry, Harvard Medical School, Massachusetts General Hospital, Charlestown, MA, USA; A. Winokur, Department of Psychiatry, University of Connecticut Health Center, Farmington, CT, USA.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yang, L.P.H., Deeks, E.D. Sublingual Zolpidem (Edluar™; Sublinox™). CNS Drugs 26, 1003–1010 (2012). https://doi.org/10.1007/s40263-012-0009-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40263-012-0009-y

Keywords

Search

Navigation